Finding 481139 (2022-009)

Material Weakness Repeat Finding
Requirement
C
Questioned Costs
-
Year
2022
Accepted
2024-08-15
Audit: 317252
Organization: Unity Health Care, Inc. (MD)
Auditor: Bdo USA PC

AI Summary

  • Core Issue: 12 out of 34 reimbursement requests lacked proper documentation for timely review and approval, violating federal requirements.
  • Impacted Requirements: Non-compliance with 2 CFR Sections 200.305 and 200.302(b)(c) regarding timely fund disbursement and documentation procedures.
  • Recommended Follow-Up: Implement formal internal controls and maintain documentation for cash drawdowns and approvals to ensure compliance and accuracy.

Finding Text

Criteria: In accordance with 2 CFR Section 200.305, non-Federal entities must minimize the time elapsing between the transfer of funds from the Federal agency or pass-through entity and disbursement by the Corporation for program costs and proportionate share of allowable indirect costs. Additionally, 2 CFR Section 200.302(b)(c) requires non-Federal entities to establish written procedures to implement the requirements 2 CFR Section 200.305. The Federal Acquisition Regulation clause at 48 CFR section 52.216-7(b)(1) requires that the non-Federal entity request reimbursement for only allocable, allowable, and reasonable contract costs that have already been paid or incurred. Condition: During our testing of reimbursement requests, we noted that 12 out of 34 sampled requests did not have adequate supporting documentation as to evidence of timely review and approval. Cause: The Corporation did not maintain detailed listings of eligible costs incurred at the time of reimbursement request to support the amount of reimbursement requested in the Payment Management System. Additionally, the Corporation did not maintain documentation of such review or approval that such costs were incurred prior to request for reimbursement, or the amount requested was in accordance with 2 CFR Section 200.305. Eligible cost listings to support amounts drawn during the grant period in total were reconstructed to support annual activity. Effect or Potential Effect: Requests for reimbursement per the Payment Management System may not have minimized the time elapsing between payment by the Federal agency or pass through and disbursement by the Corporation and the amounts requested for reimbursement may be inaccurate. Questioned costs: Unknown Context: We selected 34 reimbursement requests submitted through the Payment Management System and DC Portal during the year ended December 31, 2022. The Corporation was unable to provide evidence of timely review and approval of 12 requests out of 34. Additionally, cost listings were not maintained and were recreated to validate amount of the draw downs during the fiscal year. This is a condition identified per review of the Corporation’s compliance with specified requirements using a statistically valid sample. Repeat finding: This is a repeat finding from prior year. This was reported as finding 2021-009 in the 2021 report. Recommendation: We recommend the Corporation establish formal internal controls, and documentation of their performance, relating to the determination of cash drawn downs and review and approval of drawn downs by appropriate personnel who is knowledgeable of such requirements. View of Responsible Officials: Due to turnover of several key financial executives and personnel and lack of formal documentation of current policies and procedures, the Corporation neither retained support eligible cost listings at the time of reimbursement request nor documented review or approval of such reimbursement request.

Categories

Cash Management Subrecipient Monitoring Allowable Costs / Cost Principles Matching / Level of Effort / Earmarking

Other Findings in this Audit

  • 481113 2022-004
    Material Weakness Repeat
  • 481114 2022-005
    Material Weakness Repeat
  • 481115 2022-006
    Material Weakness Repeat
  • 481116 2022-007
    Significant Deficiency Repeat
  • 481117 2022-009
    Material Weakness Repeat
  • 481118 2022-010
    Significant Deficiency Repeat
  • 481119 2022-011
    Significant Deficiency Repeat
  • 481120 2022-004
    Material Weakness Repeat
  • 481121 2022-005
    Material Weakness Repeat
  • 481122 2022-006
    Material Weakness Repeat
  • 481123 2022-007
    Significant Deficiency Repeat
  • 481124 2022-009
    Material Weakness Repeat
  • 481125 2022-010
    Significant Deficiency Repeat
  • 481126 2022-011
    Significant Deficiency Repeat
  • 481127 2022-004
    Material Weakness Repeat
  • 481128 2022-005
    Material Weakness Repeat
  • 481129 2022-006
    Material Weakness Repeat
  • 481130 2022-007
    Significant Deficiency Repeat
  • 481131 2022-012
    Significant Deficiency
  • 481132 2022-013
    Significant Deficiency
  • 481133 2022-016
    Significant Deficiency
  • 481134 2022-017
    Significant Deficiency
  • 481135 2022-004
    Material Weakness Repeat
  • 481136 2022-005
    Material Weakness Repeat
  • 481137 2022-006
    Material Weakness Repeat
  • 481138 2022-008
    Significant Deficiency Repeat
  • 481140 2022-016
    Significant Deficiency
  • 481141 2022-004
    Material Weakness Repeat
  • 481142 2022-005
    Material Weakness Repeat
  • 481143 2022-006
    Material Weakness Repeat
  • 481144 2022-007
    Significant Deficiency Repeat
  • 481145 2022-016
    Significant Deficiency
  • 481146 2022-004
    Material Weakness Repeat
  • 481147 2022-005
    Material Weakness Repeat
  • 481148 2022-006
    Material Weakness Repeat
  • 481149 2022-010
    Significant Deficiency Repeat
  • 481150 2022-014
    Material Weakness
  • 481151 2022-015
    Significant Deficiency
  • 481152 2022-016
    Significant Deficiency
  • 1057555 2022-004
    Material Weakness Repeat
  • 1057556 2022-005
    Material Weakness Repeat
  • 1057557 2022-006
    Material Weakness Repeat
  • 1057558 2022-007
    Significant Deficiency Repeat
  • 1057559 2022-009
    Material Weakness Repeat
  • 1057560 2022-010
    Significant Deficiency Repeat
  • 1057561 2022-011
    Significant Deficiency Repeat
  • 1057562 2022-004
    Material Weakness Repeat
  • 1057563 2022-005
    Material Weakness Repeat
  • 1057564 2022-006
    Material Weakness Repeat
  • 1057565 2022-007
    Significant Deficiency Repeat
  • 1057566 2022-009
    Material Weakness Repeat
  • 1057567 2022-010
    Significant Deficiency Repeat
  • 1057568 2022-011
    Significant Deficiency Repeat
  • 1057569 2022-004
    Material Weakness Repeat
  • 1057570 2022-005
    Material Weakness Repeat
  • 1057571 2022-006
    Material Weakness Repeat
  • 1057572 2022-007
    Significant Deficiency Repeat
  • 1057573 2022-012
    Significant Deficiency
  • 1057574 2022-013
    Significant Deficiency
  • 1057575 2022-016
    Significant Deficiency
  • 1057576 2022-017
    Significant Deficiency
  • 1057577 2022-004
    Material Weakness Repeat
  • 1057578 2022-005
    Material Weakness Repeat
  • 1057579 2022-006
    Material Weakness Repeat
  • 1057580 2022-008
    Significant Deficiency Repeat
  • 1057581 2022-009
    Material Weakness Repeat
  • 1057582 2022-016
    Significant Deficiency
  • 1057583 2022-004
    Material Weakness Repeat
  • 1057584 2022-005
    Material Weakness Repeat
  • 1057585 2022-006
    Material Weakness Repeat
  • 1057586 2022-007
    Significant Deficiency Repeat
  • 1057587 2022-016
    Significant Deficiency
  • 1057588 2022-004
    Material Weakness Repeat
  • 1057589 2022-005
    Material Weakness Repeat
  • 1057590 2022-006
    Material Weakness Repeat
  • 1057591 2022-010
    Significant Deficiency Repeat
  • 1057592 2022-014
    Material Weakness
  • 1057593 2022-015
    Significant Deficiency
  • 1057594 2022-016
    Significant Deficiency

Programs in Audit

ALN Program Name Expenditures
93.224 Consolidated Health Centers (community Health Centers, Migrant Health Centers, Health Care for the Homeless, and Public Housing Primary Care) $4.41M
93.788 Opioid Str $1.46M
93.217 Family Planning_services $1.34M
10.557 Special Supplemental Nutrition Program for Women, Infants, and Children $1.29M
93.914 Hiv Emergency Relief Project Grants $898,253
93.918 Grants to Provide Outpatient Early Intervention Services with Respect to Hiv Disease $584,947
93.837 Cardiovascular Diseases Research $402,416
93.917 Hiv Care Formula Grants $367,131
93.426 Improving the Health of Americans Through Prevention and Management of Diabetes and Heart Disease and Stroke $178,078
93.994 Maternal and Child Health Services Block Grant to the States $169,521
93.268 Immunization Cooperative Agreements $167,318
93.236 Grants to States to Support Oral Health Workforce Activities $104,190
93.898 Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations $81,214
93.526 Affordable Care Act (aca) Grants for Capital Development in Health Centers $77,935
93.889 National Bioterrorism Hospital Preparedness Program $33,398
93.279 Drug Abuse and Addiction Research Programs $31,446
93.297 Teenage Pregnancy Prevention Program $14,271
93.855 Allergy, Immunology and Transplantation Research $1,571